
‘Mount Everest air' could hold key to reversing Parkinson's symptoms, study finds
The research, published in the journal Nature Neuroscience, shows that faulty cellular processes in the brain cause a build-up of excess oxygen molecules, leading to Parkinson's symptoms.
The excess oxygen appears to drive the breakdown of cells in the brain, suggesting that limiting oxygen intake could help slow or reverse symptoms, say researchers from Harvard Medical School.
Parkinson's patients experience a progressive loss of neurons in the brain, leading to tremors and slowed movements, with the disease affecting over 10 million people worldwide.
Neurons affected by Parkinson's also tend to accumulate toxic protein clumps called Lewy bodies, with some research suggesting that these clumps interfere with the function of mitochondria, the powerhouse of the cell, .
Anecdotal case studies have shown that people with Parkinson's seem to fare better at high altitudes.
'Based on this evidence, we became very interested in the effect of hypoxia on Parkinson's disease,' said study author Fumito Ichinose.
'We first saw that low oxygen could alleviate brain-related symptoms in some rare diseases where mitochondria are affected, such as Leigh syndrome and Friedreich's ataxia... That raised the question: Could the same be true in more common neurodegenerative diseases like Parkinson's?' said Vamsi Mootha, another author of the study.
In the research, scientists induced Parkinson's-like conditions in mice by injecting them with clumps of the α-synuclein proteins that seed the formation of Lewy bodies.
They then split the mice into two groups – one breathing normal air with 21 per cent oxygen, and the other continuously housed in chambers with 11 per cent oxygen, comparable to living at an altitude of about 4,800 metres (16,000 ft).
Researchers found that just three months after receiving the α-synuclein protein injections, mice breathing normal air had high levels of Lewy bodies, dead neurons, and severe movement problems.
On the other hand, the mice kept in low-oxygen conditions didn't lose any neurons and showed no movement problems, despite developing Lewy bodies.
The results show that while hypoxia couldn't stop the formation of Lewy bodies, it was protecting neurons from the damaging effects of these protein clumps.
Researchers hope the findings could serve as a new way to interpret and treat Parkinson's without targeting α-synuclein or Lewy bodies.
Scientists also found that the low-oxygen treatment still worked even when hypoxia was introduced six weeks after the injection, when symptoms were already appearing.
After six weeks, the mice's motor skills rebounded, their anxiety-like behaviours faded, and the loss of neurons in the brain stopped, researchers found.
When scientists analysed the brain cells of the mice, they discovered that mice with Parkinson's symptoms had much higher levels of oxygen in some parts of the brain than control mice and those that had breathed low-oxygen air.
They suspect the excess oxygen likely resulted from mitochondrial dysfunction.
With the damaged cell powerhouses unable to use oxygen efficiently, oxygen was building up to damaging levels, researchers say.
'Too much oxygen in the brain turns out to be toxic. By reducing the overall oxygen supply, we're cutting off the fuel for that damage,' Dr Mootha said.
Scientists are working on 'hypoxia in a pill' drugs which mimic the effects of low oxygen to treat disorders stemming from mitochondrial dysfunction.
But while the results are encouraging, researchers caution that more research is needed before the findings can be directly used to treat Parkinson's in humans.
'It may not be a treatment for all types of neurodegeneration...but it's a powerful concept – one that might shift how we think about treating some of these diseases,' Dr Mootha said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
26 minutes ago
- Reuters
At least 600 US CDC employees are getting final termination notices, AP reports
Aug 20 (Reuters) - At least 600 employees of the U.S. Centers for Disease Control and Prevention are receiving permanent termination notices, the Associated Press reported on Wednesday, citing the American Federation of Government Employees. The report added that the notices were sent out this week, and many employees have not yet received them, according to the union, which represents more than 2,000 dues-paying members at the agency. The Trump administration began mass layoffs of 10,000 staffers at U.S. health agencies in April, as part of a sweeping overhaul aimed at shrinking the federal government and reducing spending. The U.S. Department of Health and Human Services, which oversees the CDC, and the American Federation of Government Employees did not immediately respond to Reuters' requests for comment.


Reuters
an hour ago
- Reuters
Exclusive: CVS holds off adding Gilead's new HIV prevention shot to drug coverage lists
Aug 20 (Reuters) - CVS Health (CVS.N), opens new tab, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' (GILD.O), opens new tab new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medicine's proven effectiveness. CVS based the decision on clinical, financial, and regulatory factors, spokesperson David Whitrap said in an email. It also will not cover Yeztugo under its Affordable Care Act formularies, since its ACA preventive program follows recommendations and mandates from the U.S. Department of Health and Human Services (HHS), Whitrap said. Current HIV prevention recommendations from the U.S. Preventive Services Task Force (USPSTF), which is supported by HHS, include only three older drugs. A source familiar with the situation suggested that Gilead is still negotiating with CVS over Yeztugo, a twice-yearly injection with a U.S. list price of more than $28,000 a year. The decision by CVS is "a grave disappointment and frankly a missed opportunity," said Mitchell Warren, executive director of the AIDS nonprofit AVAC. "It does reflect a price that is too high and a U.S. pharmaceutical pricing structure that is frankly not sustainable." He and other AIDS activists have said Yeztugo could be a transformative tool in ending the 44-year-old epidemic that infects 1.3 million people a year and is estimated by the World Health Organization to have killed more than 42 million. Pharmacy benefit managers, or PBMs, act as middlemen between drug companies and consumers. They negotiate volume discounts with drug manufacturers on behalf of employers and health plans based on coverage terms. The three largest - CVS Caremark, UnitedHealth Group's (UNH.N), opens new tab OptumRX and Cigna's (CI.N), opens new tab Express Scripts - control about 70%, opens new tab of specialty drug prescriptions in the U.S. Optum said Yeztugo will be reviewed for coverage in the coming weeks, while Express Scripts did not respond to requests for comment. Gilead, which declined to comment, said earlier this month it is on track to secure 75% U.S. insurer coverage of Yeztugo by year-end and 90% coverage by June 2026. Its CEO, Daniel O'Day, has said that half of every dollar spent on medicines in the U.S. goes to PBMs and other entities that do not make drugs. U.S. government healthcare programs, including the Veterans Administration and the Medicare program for people over age 65, have already added Yeztugo to coverage lists. Gilead said earlier this month that several state-run Medicaid plans, including California and New York, were covering the drug. Gilead, its investors, and AIDS activists have high hopes for Yeztugo. Approved in June for people at high risk of HIV, the drug was shown to be nearly 100% effective at preventing infection in large trials, fueling fresh optimism about limiting the spread of HIV. Some analysts have warned that a recent Supreme Court ruling affirming broad HHS authority, opens new tab over the USPSTF could affect coverage prospects while Robert F. Kennedy Jr is in charge of the agency. Medical groups have expressed alarm about reports that Kennedy could replace members of the task force. The 16-member task force reviews evidence and public input, then recommends preventive services that catch disease early or prevent worsening, which insurers must cover without patient cost-sharing. For HIV prevention, it endorses daily PrEP pills Truvada, which is available as a generic, and Gilead's Descovy, as well as ViiV Healthcare's bimonthly shot Apretude. Gilead's O'Day has stressed that the lifetime cost of treating an HIV patient can exceed $1 million, making a preventive treatment cost effective.


Daily Mail
an hour ago
- Daily Mail
Woman can no longer walk, talk or feed herself after Brazilian butt lift cosmetic surgery went horribly wrong
A Florida woman has been left fighting for her life after a botched Brazilian butt lift operation from an unqualified surgeon, her husband alleged in a new lawsuit. Daidys Pena Garces, 50, underwent the procedure, also known as a BBL, at A&E Med Spa in Miami on May 15, 2023. The operation was performed by Dr. Fermin Morales, who only weeks later caused another BBL patient's death following the procedure, state health officials said. The operation involves taking fat from the hips, abdomen and other areas via liposuction, before injecting it into the buttocks. Recipients hope for a bigger, more pert behind, but experts have long warned of the dangers of BBLs, which can prove fatal. Less than a month after her procedure, Garces suffered a pulmonary embolism that caused severe brain damage and left her unable to walk, talk or feed herself, according to her husband, Jorge Fernandez. 'She was my first, like my first love,' he told WSVN. '[Now] she never more will talk or walk or eat by herself.' Fernandez filed a medical malpractice lawsuit against A&E Med Spa and Morales, who is certified as a general surgeon, not a plastic surgeon, in June. The lawsuit claims Garces was not made aware of the risks associated with the elective surgery or of Morales' qualifications because the med spa withheld information from her. 'This pulmonary embolism occurred because of this surgery,' Fernandez's attorney, Lavenia Santos, told WSVN. According to the lawsuit, Garces was never made aware that Morales was not a plastic surgeon. 'From representations made by the agents at A&E Med Spa, any reasonable person would be led to believe that Fermin Esteban Morales, M.D., was Board Certified in Plastic Surgery when, in fact, he was not,' the court document said. 'Garces would not have undergone the high-risk plastic surgery procedure had she known that [Morales] was not a trained and board-certified plastic surgeon.' In Florida, there is no legal requirement that a doctor be a board-certified plastic surgeon to preform a BBL. 'The woman has no idea that she is not being cared for by a board-certified plastic surgeon. That's just wrong,' Santos said. 'If the public knew that, they probably not be so willing to go, regardless of price. What happened to her shouldn't happen to anyone.' A GoFundMe page set up for Garces and Fernandez said that she 'had no idea the surgeon was unqualified.' 'Daidys required emergency medical care and was hospitalized for seven months due to the pulmonary embolism,' it read. 'Now, Daidys is unable to perform any activities of daily living without assistance. Along with facing an extended recovery process, she is now burdened with growing medical bills and ongoing treatments.' Additionally, the lawsuit argues that Garces was not properly made aware of the medical risks of the operation because all of the informed consent documents she signed were in English, not her primary language of Spanish. In their response filing, A&E Med Spa denied all of the allegations. Their attorneys told the local news station that Morales no longer works there. The Daily Mail contacted A&E Med Spa, their attorneys, Morales and his current employer, New Life Plastic Surgery, for comment. In February, Morales was accused by the Florida Department of Health of causing a BBL patient's death in 2023, the same year as Garces' operation, the Miami Herald reported. On June 7, 2023, Morales allegedly injected fat into the wrong area during a 40-year-old woman's BBL procedure at Doral's Venus Cosmetic Institute/DASO Plastic Surgery, located in a strip mall. The woman died the next day and her autopsy found 'copious globules of lacerated fat throughout her left and right superficial and deep gluteal muscles' and 'fat globules in blood' in her left lung vessels.